Collectively, these contemporary investigations underscore the potential value of PSMA theragnostic approaches for improving disease diagnosis and prognosis, as well as the feasibility for targeted drug delivery strategies in pet dogs with PSMA-expressing cancers. This evidence concerns the gene FOLH1 and cancer.